MISSISSAUGA,
ON, Oct. 11, 2012 /PRNewswire/
- YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug
development company advancing hematology and cancer related
products, today announced that the results of its Phase I/II Study
of CYT387, a JAK1/JAK2 inhibitor currently being evaluated for the
treatment of myelofibrosis, have been selected by the ASH Program
Committee for presentation in an Oral Session at the 2012 Annual
Meeting of the American Society of Hematology to be held in
Atlanta, Georgia on December 9, 2012.
"CYT387 could prove to be an important and
differentiated therapeutic for patients with myelofibrosis; the
interim data we have reported to date have been highly
encouraging," said Dr. Nick Glover,
President and CEO of YM BioSciences. "We look forward to the
release of final nine-month data from the Phase I/II CYT387 study
at ASH, as well as further ongoing data from the many patients who
continue to benefit from the drug in its Extension trial."
Title: Phase I/II Study of CYT387, a
JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis
Session Name: 634. Myeloproliferative Syndromes - Clinical:
Myeloproliferative Neoplasms - Novel Therapies I
Session Date: Sunday, December
9, 2012; 4:30 PM - 6:00 PM
(Presentation Time: 5:15
PM)
Location: Georgia World Congress Center, Room
B213-B214
About YM BioSciences
YM BioSciences Inc. is a drug development company primarily
focused on advancing CYT387, an orally administered inhibitor of
both the JAK1 and JAK2 kinases, which have been implicated in a
number of hematological and immune cell disorders including
myeloproliferative neoplasms and inflammatory diseases as well as
certain cancers. Positive interim results have been reported from a
Phase I/II trial of CYT387 in 166 patients with myelofibrosis. YM's
portfolio also includes nimotuzumab, a humanized monoclonal
antibody targeting EGFR with an enhanced side-effect profile over
currently marketed EGFR-targeting antibodies. Nimotuzumab is being
evaluated in numerous Phase II and III trials worldwide. In
addition, YM has several preclinical programs underway with
candidates from its library of novel compounds identified through
internal research conducted at YM BioSciences Australia.
This press release may contain
forward-looking statements, which reflect the Company's current
expectation regarding future events. These forward-looking
statements involve risks and uncertainties that may cause actual
results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not
limited to, changing market conditions, the successful and timely
completion of clinical studies, the establishment of corporate
alliances, the impact of competitive products and pricing, new
product development, uncertainties related to the regulatory
approval process or the ability to obtain drug product in
sufficient quantity or at standards acceptable to health regulatory
authorities to complete clinical trials or to meet commercial
demand; and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not
limited to the following: that CYT387 and nimotuzumab will generate
positive efficacy and safety data in ongoing and future clinical
trials, and that YM as well as CIMYM's various licensees will
complete their respective clinical trials and disclose data within
the timelines communicated in this release. Except as required by
applicable securities laws, we undertake no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
SOURCE YM BioSciences Inc.